Sant Pau - Institut de Recerca

Main lines of research

Clinical Trials with no Therapeutic Benefits to Volunteer Participants

Phase I clinical trials (healthy volunteers) whose main objectives include: first-timein-humans, safety and tolerability (local, systemic/dermatological, ophthalmological, vaginal), pharmacokinetics, bioavailability and bioequivalence (generic drugs), pharmacodynamics, interactions (drug-drug/drug-food), evaluation and characterization of biomarkers, proofs of concept, acceptability and preference studies.
Follow-up studies in populations with the same or different characteristics (elderly, obese, postmenopausal, with liver or kidney failure).
Collaboration with clinical services to conduct phase II/III studies.

Neuro-Physio-Pharmacology of Sleep/Wake States

Investigate human brain activity in sleep and wakefulness, mechanisms involved in these states, problems derived from sleep disturbances and possible interventions.
Approach the phenomenon as a continuum: appropriate interpretation of the impact of a certain intervention, whether pharmacological or not, should take into account the complementarity of evaluations performed during sleep and during wakefulness.
Develop studies that consider the 24-hour day/night cycle as the phenomenon under study cannot be evaluated without taking this interactivity into account.
Develop psychomotor performance tests, subjective evaluation scales, neurophysiologic recordings (quantitative EEG, evoked-sensorial potentials and polysomnography), psychophysiological tests and pupillometric tests.

Challenges

Consolidate and strengthen leadership in this field in Spain, conserve relationships with the pharmaceutical industry on a national level and strengthen and extend relations abroad with multinational enterprises and industries from other sectors.
Broaden the range of questions to address in research projects along the lines of the neuro-physio-pharmacology of sleep/wake states, focusing on pharmacotherapeutic objectives and also on physiopathologic objectives in related fields, such as dreams.
Develop neurophysiologic recording performance in ambulatory conditions, simplifying
participation of volunteers but not lowering the quality of data obtained (non-negotiable element of their application as a research variable).
Promote dissemination of our activity with a dual objective: to return knowledge generated to society and demystify research in humans, bringing it closer to the community so as to foster participation in clinical trials (particularly in specific sectors of the populations, such as the elderly).
Set up educational activities related to our two main research lines: the application of good clinical practices in clinical research into sleep medicine and its medical (pathology, and treatment) and social (quality of life, prevention of accident risk) consequences.

Group coordination

ANTONIJOAN ARBOS, ROSA MARIA FGS
rantonijoana@santpau.cat

Members

Castillo Ocaña, Marta IR
Cortes Pestana, Mayro Jaime FGS
Fraga Varela, Angela IR
Garrido Sanchez, Maria Teresa IR
Gonzalez Cuadros, Mireia IR
Martinez Bonifacio, David IR
Martinez Martinez, Maria Isabel IR
Molina Perello, Pol IR
Pontes Garcia, Caridad FGS
Sanchez Nuñez, Isabel IR

Publications 2024

(JIF 2024)

-Coimbra J, Puntes M, Molina P, Gich I, Antonijoan R, Gilaberte I, Arranz P, Sánchez C. Comparative inhibition by oral bilastine, parenteral dexchlorpheniramine, and a new bilastine parenteral (i.v. and i.m.) formulation of histamine-induced wheal and flare response: A randomised phase I trial. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2024; 203:106900. DOI:10.1016/j.ejps.2024.106900. PMID:39265704. IF:4,700 (Q1/2D). Document type: Article.

-Filippi-Arriaga F, Molina P, Delgado-Espinoza CE, Antonijoan R. A cross-sectional study of Phase I Clinical Trials authorized in Spain: An analysis of characteristics and times of execution based on experience. Medicina Clínica. 2024; 163(11):577-82. DOI:10.1016/j.medcli.2024.06.001. PMID:39043476. IF:2,100 (Q2/3D). Document type: Article.

-Padro T, Santisteban V, Huedo P, Puntes M, Aguiló M, Espadaler J, Badimon L. Lactiplantibacillus plantarum strains KABP011, KABP012, and KABP013 modulate bile acids and cholesterol metabolism in humans. CARDIOVASCULAR RESEARCH. 2024; 120(7). DOI:10.1093/cvr/cvae061. PMID:38525555. IF:13,300 (Q1/1D). Document type: Article.

-Pesiou S, Barcelo R, Papazisis G, Torres F, Pontes C. Prevalence of use of on-label and off-label psychotropics in the Greek pediatric population. Frontiers in Pharmacology. 2024; 15:1348887. DOI:10.3389/fphar.2024.1348887. PMID:38549664. IF:4,800 (Q1/2D). Document type: Article.

-Piera J, Carot G, Ramiro M, Nogueras MM, Folguera J, Ródenas P, Jiménez A, Navarro TD, Palacios J, Fajardo JC, Campillo JU, Vela E, Monterde D, Valero D, Bonet T, Tarrasó G, Cantenys R, Fabregat P, Oliveros BG, Berdún J, Michelena X, Cano I, González R, Roca J, Solans O, Pontes C, Pérez P. A 25-Year Retrospective of Health IT Infrastructure Building: The Example of the Catalonia Region. JOURNAL OF MEDICAL INTERNET RESEARCH. 2024; 26:e58933. DOI:10.2196/58933. PMID:39556831. IF:6,000 (Q1/1D). Document type: Article.

-Pieren M, Gutiérrez AA, Arbós R, Boyle GW, Davila M, Davy M, Gitzinger M, Husband L, Martínez MS, Mazarro DO, Pefani E, Penman SL, Remuiñán MJ, Vlasakakis G, Zeitlinger M, Dale GE. First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2024; 79(6). DOI:10.1093/jac/dkae107. PMID:38656557. IF:3,600 (Q2/3D). Document type: Article.

-Ríos J, Sapena V, Marino Z, Bruix J, Forns X, Morros R, Reig M, Torres F, Pontes C. Incidence of Liver and Non-liver Cancers After Hepatitis C Virus Eradication: A Population-Based Cohort Study. Drugs-Real World Outcomes. 2024; 11(3). DOI:10.1007/s40801-024-00437-y. PMID:38874848. IF:1,900 (Q3/7D). Document type: Article.

-Santisteban V, Muñoz N, López A, Puntes M, Badimon L, Padro T. Efficacy of Food Industry By-Product ß-Glucan/Chitin-Chitosan on Lipid Profile of Overweight and Obese Individuals: Sustainability and Nutraceuticals. Nutrients. 2024; 16(19):3420. DOI:10.3390/nu16193420. PMID:39408385. IF:5,000 (Q1/2D). Document type: Article.

-Vallano A, Pontes C. Escalating costs of innovative medicines: perspective and proposals. Frontiers in Public Health. 2024; 12:1449707. DOI:10.3389/fpubh.2024.1449707. PMID:39381757. IF:3,400 (Q1/2D). Document type: Article.

Publications 2023

(JIF 2023)

-Mas E, Ferreri L, Cardona G, Zatorre RJ, Pla F, Antonijoan RM, Riba J, Valle M, Rodriguez A. The role of opioid transmission in music-induced pleasure. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. 2023; 1520(1). DOI:10.1111/nyas.14946. PMID:36514207. IF:4,100 (Q1/2D). Document type: Article.

-Moraga P, Prieto P, Conradie A, Benhayoun M, Rousell V, Davy M, Fuhr U, Antonijoan Arbos R, Abad F, Portolés A, Van Duinen J, Carcas AJ, Borobia AM. Academia and industry agreement on a feasibility tool for first-time-in-human clinical trial units. CTS-Clinical and Translational Science. 2023; 16(12). DOI:10.1111/cts.13655. PMID:37818923. IF:3,100 (Q2/5D). Document type: Article.

Publications 2022

(JIF 2022)

Coimbra J, Puntes M, Gich I, Martinez J, Molina P, Antonijoan R, Campo C, Labeaga L. Lack of Clinical Relevance of Bilastine-Food Interaction in Healthy Volunteers: A Wheal and Flare Study. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY. 2022; 183(12). DOI:10.1159/000524856. PMID:35700691. IF:2,8 (Q3/6D). Document type: Article.
Corrochano M, Acosta R, Mojal S, Miqueleiz S, Rodriguez D, Quijada MA, Fraga E, Castillo M, Amaro K, Albiol N, Soria JM, Antonijoan RM, Souto JC. Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19. JOURNAL OF THROMBOSIS AND THROMBOLYSIS. 2022; 53(1). DOI:10.1007/s11239-021-02507-2. PMID:34138399. IF:4 (Q2/4D). Document type: Article.
Melo MC, Santeularia MT, Rius C, Gich IJ, Català E. Influence of comorbidities on pain intensity in patients with chronic low back pain. MEDICINA CLINICA. 2022; 159(2). DOI:10.1016/j.medcli.2021.09.023. PMID:34879972. IF:3,9 (Q2/4D). Document type: Article.
Ona G, Sampedro F, Romero S, Valle M, Camacho V, Migliorelli C, Mananas MA, Antonijoan RM, Puntes M, Coimbra J, Ballester MR, Garrido M, Riba J. The Kappa Opioid Receptor and the Sleep of Reason: Cortico-Subcortical Imbalance Following Salvinorin-A. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2022; 25(1). DOI:10.1093/ijnp/pyab063. PMID:34537829. IF:4,8 (Q1/3D). Document type: Article.
Soria JM, Mojal S, Martinez A, Acosta FR, López S, Miqueleiz S, Rodriguez D, Quijada MA, Cardenas A, Vidal F, Remacha A, Antonijoan RM, Souto JC. A validated clinical-genetic score for assessing the risk of thrombosis in patients with COVID-19 receiving thromboprophylaxis. HAEMATOLOGICA. 2022; 107(9). DOI:10.3324/haematol.2022.281068. PMID:35545920. IF:10,1 (Q1/2D). Document type: Article.

Publications 2021

Antonijoan RM, Ferrero JM, Coimbra J, Puntes M, Martinez J, Arevalo MI, Mascaro C, Molinero C, Buesa C, Maes T. First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat. CNS DRUGS. 2021; 35(3). DOI:10.1007/s40263-021-00797-x. PMID:33755924. IF: 6,497
Corominas H, Castellvi I, Pomar V, Antonijoan R, Mur I, Matas L, Gich I, de Benito N, Laiz A, Castillo D, Villamarin L, Filella D, Mill AM, Quijada MA, Puig M, Casademont J, Domingo P. Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort. CLINICAL IMMUNOLOGY. 2021; 223:108631. DOI:10.1016/j.clim.2020.108631. PMID:33189888. IF: 10,190
Ferreri L, Mas E, Cardona G, Zatorre RJ, Antonijoan RM, Valle M, Riba J, Ripolles P, Rodriguez A. Dopamine modulations of reward-driven music memory consolidation. Annals of the New York Academy of Sciences. 2021; 1502(1). DOI:10.1111/nyas.14656. PMID:34247392. IF: 6,499
Llorca V, Palacios R, Routo DR, Buil E, Adrados M, Gich I, Bioque M, Mur M. High neutrophil-lymphocyte ratio upon admission is associated with better response in psychotic depression. JOURNAL OF PSYCHIATRIC RESEARCH. 2021; 143. DOI:10.1016/j.jpsychires.2021.08.021. PMID:34438202. IF: 5,250
Lopez L, Domenech E, Roguera M, Gich I, Farre M, Rodrigo C, Montane E. Spontaneous Reporting of Adverse Drug Reactions in a Pediatric Population in a Tertiary Hospital. Journal of Clinical Medicine. 2021; 10(23):5531. DOI:10.3390/jcm10235531. PMID:34884233. IF: 4,964
Magallares B, Lobo D, Castellvi I, Moya P, Gich I, Martinez L, Park H, Millan AM, Laiz A, Diaz C, Fernandez S, Corominas H. Assessment of EULAR/ACR-2019, SLICC-2012 and ACR-1997 Classification Criteria in SLE with Longstanding Disease. Journal of Clinical Medicine. 2021; 10(11):2377. DOI:10.3390/jcm10112377. PMID:34071275. IF: 4,964
Munoz FZ, Rios M, Roe E, Bernabeu J, Montserrat MT, Puig L, Gich I, Baselga E. Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage A Randomized Clinical Trial. JAMA Dermatology. 2021; 157(5). DOI:10.1001/jamadermatol.2021.0596. PMID:33825828. IF: 11,816
Navarro DF, Garcia AL, de Guzman EN, Rabassa M, Campos RZ, Pardo H, Ricci I, Canelo C, Meneses JF, Yepes JJ, Kuindersma J, Saladich IG, Alonso P. Vitamin D recommendations in clinical guidelines: A systematic review, quality evaluation and analysis of potential predictors. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2021; 75(11):e14805. DOI:10.1111/ijcp.14805. PMID:34486779. IF: 3,149
Tundidor D, Meek CL, Yamamoto J, Martinez C, Gich I, Feig DS, Murphy HR, Corcoy R. Continuous Glucose Monitoring Time-in-Range and HbA(1c) Targets in Pregnant Women with Type 1 Diabetes. Diabetes Technology & Therapeutics. 2021; 23(10). DOI:10.1089/dia.2021.0073. PMID:33945304. IF: 7,337
Weersink RA, Alvarez-Alvarez I, Medina-Cáliz I, Sanabria-Cabrera J, Robles-Díaz M, Ortega-Alonso A, García-Cortés M, Bonilla E, Niu H, Soriano G, Jimenez-Perez M, Hallal H, Blanco S, Kaplowitz N, Lucena MI, Andrade RJ. Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old. CLINICAL PHARMACOLOGY & THERAPEUTICS. 2021;109(4):1147-1158. DOI:10.1002/cpt.2108. PMID: 33179256. IF: 6,903

2017 Scientific Report – Pharmacological Res in Human

Introduction

Main lines of research

Clinical Trials with no Therapeutic Benefits to Volunteer Participants

Phase I clinical trials (healthy volunteers) whose main objectives include: first-timein-humans, safety and tolerability (local, systemic/dermatological, ophthalmological, vaginal), pharmacokinetics, bioavailability and bioequivalence (generic drugs), pharmacodynamics, interactions (drug-drug/drug-food), evaluation and characterization of biomarkers, proofs of concept, acceptability and preference studies.
Follow-up studies in populations with the same or different characteristics (elderly, obese, postmenopausal, with liver or kidney failure).
Collaboration with clinical services to conduct phase II/III studies.

Neuro-Physio-Pharmacology of Sleep/Wake States

Investigate human brain activity in sleep and wakefulness, mechanisms involved in these states, problems derived from sleep disturbances and possible interventions.
Approach the phenomenon as a continuum: appropriate interpretation of the impact of a certain intervention, whether pharmacological or not, should take into account the complementarity of evaluations performed during sleep and during wakefulness.
Develop studies that consider the 24-hour day/night cycle as the phenomenon under study cannot be evaluated without taking this interactivity into account.
Develop psychomotor performance tests, subjective evaluation scales, neurophysiologic recordings (quantitative EEG, evoked-sensorial potentials and polysomnography), psychophysiological tests and pupillometric tests.

Challenges

Consolidate and strengthen leadership in this field in Spain, conserve relationships with the pharmaceutical industry on a national level and strengthen and extend relations abroad with multinational enterprises and industries from other sectors.
Broaden the range of questions to address in research projects along the lines of the neuro-physio-pharmacology of sleep/wake states, focusing on pharmacotherapeutic objectives and also on physiopathologic objectives in related fields, such as dreams.
Develop neurophysiologic recording performance in ambulatory conditions, simplifying
participation of volunteers but not lowering the quality of data obtained (non-negotiable element of their application as a research variable).
Promote dissemination of our activity with a dual objective: to return knowledge generated to society and demystify research in humans, bringing it closer to the community so as to foster participation in clinical trials (particularly in specific sectors of the populations, such as the elderly).
Set up educational activities related to our two main research lines: the application of good clinical practices in clinical research into sleep medicine and its medical (pathology, and treatment) and social (quality of life, prevention of accident risk) consequences.

Team

Group coordination

ANTONIJOAN ARBOS, ROSA MARIA FGS
rantonijoana@santpau.cat

Members

Scientific output

Coimbra J, Puntes M, Gich I, Martinez J, Molina P, Antonijoan R, Campo C, Labeaga L. Lack of Clinical Relevance of Bilastine-Food Interaction in Healthy Volunteers: A Wheal and Flare Study. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY. 2022; 183(12). DOI:10.1159/000524856. PMID:35700691. IF:2,8 (Q3/6D). Document type: Article.
Corrochano M, Acosta R, Mojal S, Miqueleiz S, Rodriguez D, Quijada MA, Fraga E, Castillo M, Amaro K, Albiol N, Soria JM, Antonijoan RM, Souto JC. Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19. JOURNAL OF THROMBOSIS AND THROMBOLYSIS. 2022; 53(1). DOI:10.1007/s11239-021-02507-2. PMID:34138399. IF:4 (Q2/4D). Document type: Article.
Melo MC, Santeularia MT, Rius C, Gich IJ, Català E. Influence of comorbidities on pain intensity in patients with chronic low back pain. MEDICINA CLINICA. 2022; 159(2). DOI:10.1016/j.medcli.2021.09.023. PMID:34879972. IF:3,9 (Q2/4D). Document type: Article.
Ona G, Sampedro F, Romero S, Valle M, Camacho V, Migliorelli C, Mananas MA, Antonijoan RM, Puntes M, Coimbra J, Ballester MR, Garrido M, Riba J. The Kappa Opioid Receptor and the Sleep of Reason: Cortico-Subcortical Imbalance Following Salvinorin-A. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2022; 25(1). DOI:10.1093/ijnp/pyab063. PMID:34537829. IF:4,8 (Q1/3D). Document type: Article.
Soria JM, Mojal S, Martinez A, Acosta FR, López S, Miqueleiz S, Rodriguez D, Quijada MA, Cardenas A, Vidal F, Remacha A, Antonijoan RM, Souto JC. A validated clinical-genetic score for assessing the risk of thrombosis in patients with COVID-19 receiving thromboprophylaxis. HAEMATOLOGICA. 2022; 107(9). DOI:10.3324/haematol.2022.281068. PMID:35545920. IF:10,1 (Q1/2D). Document type: Article.

Publications 2021

Antonijoan RM, Ferrero JM, Coimbra J, Puntes M, Martinez J, Arevalo MI, Mascaro C, Molinero C, Buesa C, Maes T. First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat. CNS DRUGS. 2021; 35(3). DOI:10.1007/s40263-021-00797-x. PMID:33755924. IF: 6,497
Corominas H, Castellvi I, Pomar V, Antonijoan R, Mur I, Matas L, Gich I, de Benito N, Laiz A, Castillo D, Villamarin L, Filella D, Mill AM, Quijada MA, Puig M, Casademont J, Domingo P. Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort. CLINICAL IMMUNOLOGY. 2021; 223:108631. DOI:10.1016/j.clim.2020.108631. PMID:33189888. IF: 10,190
Ferreri L, Mas E, Cardona G, Zatorre RJ, Antonijoan RM, Valle M, Riba J, Ripolles P, Rodriguez A. Dopamine modulations of reward-driven music memory consolidation. Annals of the New York Academy of Sciences. 2021; 1502(1). DOI:10.1111/nyas.14656. PMID:34247392. IF: 6,499
Llorca V, Palacios R, Routo DR, Buil E, Adrados M, Gich I, Bioque M, Mur M. High neutrophil-lymphocyte ratio upon admission is associated with better response in psychotic depression. JOURNAL OF PSYCHIATRIC RESEARCH. 2021; 143. DOI:10.1016/j.jpsychires.2021.08.021. PMID:34438202. IF: 5,250
Lopez L, Domenech E, Roguera M, Gich I, Farre M, Rodrigo C, Montane E. Spontaneous Reporting of Adverse Drug Reactions in a Pediatric Population in a Tertiary Hospital. Journal of Clinical Medicine. 2021; 10(23):5531. DOI:10.3390/jcm10235531. PMID:34884233. IF: 4,964
Magallares B, Lobo D, Castellvi I, Moya P, Gich I, Martinez L, Park H, Millan AM, Laiz A, Diaz C, Fernandez S, Corominas H. Assessment of EULAR/ACR-2019, SLICC-2012 and ACR-1997 Classification Criteria in SLE with Longstanding Disease. Journal of Clinical Medicine. 2021; 10(11):2377. DOI:10.3390/jcm10112377. PMID:34071275. IF: 4,964
Munoz FZ, Rios M, Roe E, Bernabeu J, Montserrat MT, Puig L, Gich I, Baselga E. Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage A Randomized Clinical Trial. JAMA Dermatology. 2021; 157(5). DOI:10.1001/jamadermatol.2021.0596. PMID:33825828. IF: 11,816
Navarro DF, Garcia AL, de Guzman EN, Rabassa M, Campos RZ, Pardo H, Ricci I, Canelo C, Meneses JF, Yepes JJ, Kuindersma J, Saladich IG, Alonso P. Vitamin D recommendations in clinical guidelines: A systematic review, quality evaluation and analysis of potential predictors. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2021; 75(11):e14805. DOI:10.1111/ijcp.14805. PMID:34486779. IF: 3,149
Tundidor D, Meek CL, Yamamoto J, Martinez C, Gich I, Feig DS, Murphy HR, Corcoy R. Continuous Glucose Monitoring Time-in-Range and HbA(1c) Targets in Pregnant Women with Type 1 Diabetes. Diabetes Technology & Therapeutics. 2021; 23(10). DOI:10.1089/dia.2021.0073. PMID:33945304. IF: 7,337
Weersink RA, Alvarez-Alvarez I, Medina-Cáliz I, Sanabria-Cabrera J, Robles-Díaz M, Ortega-Alonso A, García-Cortés M, Bonilla E, Niu H, Soriano G, Jimenez-Perez M, Hallal H, Blanco S, Kaplowitz N, Lucena MI, Andrade RJ. Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old. CLINICAL PHARMACOLOGY & THERAPEUTICS. 2021;109(4):1147-1158. DOI:10.1002/cpt.2108. PMID: 33179256. IF: 6,903

NEUROLOGICAL DISEASES, NEUROSCIENCE & MENTAL HEALTH

Pharmacological Research in Humans

Main lines of research

Clinical Trials with no Therapeutic Benefits to Volunteer Participants

Neuro-Physio-Pharmacology of Sleep/Wake States

Challenges

Group coordination

Members

Publications 2024

Publications 2023

Publications 2022

Publications 2021

Main lines of research

Clinical Trials with no Therapeutic Benefits to Volunteer Participants

Neuro-Physio-Pharmacology of Sleep/Wake States

Challenges

Group coordination

Members

Publications 2024

Publications 2023

Publications 2022

Publications 2021

Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau